Mont-Saint-Guibert, Belgium, May 14 2012 – Promethera Biosciences, a Belgian biotechnology Company developing Promethera® HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, today announces it has treated its first two patients with its innovative treatment based on allogeneic adult liver stem cell technology (HepaStem). These patients were treated and are followed at the Cliniques
Universitaires Saint-Luc (Brussels, Belgium).
Recherche de fonds
We invest in the technologies of tomorrow
Are you looking for investors for your technology projects?Contact usComplete the form